Latest Developments

03 February 2011
A5 Laboratories has received approval letter for it’s containment level 2 facility.

MONTREAL, QUEBEC–(Marketwire – 02/03/11) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) announced today the office of Biohazard and Containment Safety

01 February 2011
A5 Laboratories, Inc. Announces Successful Production of VI-1718 Interferon Product

MONTREAL, QUEBEC–(Marketwire – 02/01/11) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) announced today the successful production of its VI-1718 interferon product by its European manufacturing partner.

Current Stock Info

AFLB.OB0.00  chart+0.00
1970-01-01 00:00

Advantages

Advantages of A5 Labs Technology

A5 Laboratories provides contract analytical, regulatory and product development services to the Pharmaceutical industry. With a dedicated commitment to its client’s needs, A5 Laboratories offers a full range of services to the pharmaceutical industry in variety of fields, all in compliance with Good Laboratory Practices and current Good Manufacturing Practices regulations.

  • Use of proven platform to manufacture interferons
  • Simple and re-producable method to manufacture natural source interferon for human and veterinary applications
  • Significantly reduction of unit cost for each dose produced
  • Preliminary studies indicate 100 to 1,000 times higher potency that any other commercially available product
  • Signifcantly reduced side effects
  • Rapid approval and reduced time to revenue